Hepatobiliary Surgery and Nutrition · 6 authors, 2 centres
This summary was generated by AI from a single paper. It has not been reviewed by a clinician and is not clinical advice. Verify against the source before acting on it.
The central result is an overview of revised recommendations for surveillance, diagnosis, staging, and treatment algorithms, including a proposed shift towards earlier application of systemic immunotherapy and more aggressive multimodal treatments.
The review highlights key updates, including advocacy for optimal surveillance methods and new serum biomarkers. It notes a shift in the BCLC guidelines towards applying systemic treatments like Atezo-Bev to earlier stages, while Chinese guidelines propose more aggressive multimodal treatments combining immunotherapy with local therapies. The discussion includes discrepancies among different guidelines. The implications suggest that ongoing phase III trials may lead to future consensus on implementing immunotherapy across HCC stages. Limitations include the nature of a narrative review and the note that no validated biomarkers currently guide clinical decision-making for immunotherapy.
